2018, Number 6
Safety and effectiveness of the Hebervital in the prevention or treatment of Neutropenia. Hospital Celia Sánchez Manduley. Year: 2017
Santana PAM, Salgado SG, Sánchez SS, Garrido CEL, León LI
Full text
Language: Spanish
References: 0
Page: 1211-1220
PDF size: 136.17 Kb.
ABSTRACT
Neutropenia is a globally frequent hematological disorder, which leads to an increased susceptibility to bacterial and fungal infections. The objective of this work is to evaluate the effectiveness and safety of Hebervital administration in patients included in the clinical trial. A descriptive study was carried out in the development and execution of the clinical trial in 2017 at the Celia Sánchez Manduley hospital. The universe and sample consisted of a total of 87 patients, through the Data Collection Notebooks the information was obtained. The variables that were explored were age, sex, criteria of indication, clinical response: before and after the start of treatment with Hebervital and the evaluation of possible adverse events. The male sex predominated, the most affected ages were 18 to 25 years, the most frequent cause was represented by the administration of chemotherapy, 95.4% obtained a positive response, in addition in all cases there were no adverse events serious. The criterion of success of the therapeutics proposed in the research was fulfilled, demonstrating that the Hebervital is an essential support drug in the antineoplastic treatment.